An observational study in Adolescent, Major Depressive Disorder (MDD and Bipolar Disorder (BD), sponsored by Jiangsu Province Nanjing Brain Hospital. Recruiting at 1 site in China. Open to participants aged 10 Years to 20 Years. Per ClinicalTrials.gov, last updated 2025-11-25.
Sponsored by Jiangsu Province Nanjing Brain Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 207 studies in Depressive Disorder, Major with a site in China — 75 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.
Among the 207 studies in Depressive Disorder, Major with a site in China, this one is the 5th largest by planned enrollment of the 33 observational ones that give a count, is one of 23 that started in 2025, is one of 33 observational ones, reaches primary completion later than 71 of the 76 other live ones, and was the 175th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →75 of the 207 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:
Qilu Hospital of Shandong University · Sites in China
Ages 11–19
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
Eli Lilly and Company · Sites in China, United States, Australia and 12 more countries
Ages 18–75
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
Guo Wenbin · Sites in China
Ages 18–45
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 10 Years to 20 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
207 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 24 · Phase 3 20 · Phase 4 19
First in 2004; this study’s year is marked. 23 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 132 across 403 observational studies indexed under Depressive Disorder, Major.
Median enrollment 120 across the 174 interventional studies, 240 across the 33 observational. Of the 77 that completed or were terminated, 8 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 207 have an industry lead sponsor. The 10 most frequent:
Jiangsu Province Nanjing Brain Hospital is the lead sponsor of 22 studies on the registry; 17 are open to participants now.
Jiangsu Province Nanjing Brain Hospital has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
21 of the studies in Depressive Disorder, Major with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04984512Phase 3Sunshine Lake Pharma Co., Ltd.The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder | 2027-07 |
| NCT06913309Peking University Sixth HospitalClinical Efficacy, Safety, and Applicability of Home-based Bright Light Therapy in Outpatient Adolescents With Major Depressive Disorder | 2026-11-30 |
| NCT06409325Shanghai Mental Health CenterEffectiveness of MST Versus ECT for Major Depressive Episode | 2026-12-30 |
| NCT07873060Qilu Hospital of Shandong UniversityComparing 10 Hz rTMS and iTBS for Adolescent Depression | 2026-12-31 |
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 207 studies in Depressive Disorder, Major with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This cohort study involves the dynamic collection of clinical information from adolescent patients with major depressive episodes (including both major depressive disorder and bipolar disorder), encompassing serum parameters, physiological-behavioral signals, neuroimaging data, and neuropsychological scales. The study aims to summarize the comprehensive clinical characteristics of this population, identify new risk factors, and establish multivariate predictive models for treatment response, cognitive and emotional impairments. Furthermore, this research will thoroughly investigate the underlying neural mechanisms linking clinical manifestations and neuroimaging features in major depressive episodes.
Research Objectives:
The study will recruit participants aged 10-20 years diagnosed with major depressive disorder (MDD) or bipolar disorder (BD) according to DSM-IV criteria. Diagnoses will be confirmed using SCID-I (age ≥18) or K-SADS-PL (age \<18).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis of Major Depressive Episode will be made according to the DSM-4 criteria. Neuroimaging assessment will be performed following standardized MRI quality control and interpretation procedures, jointly evaluated by an experienced radiologist and psychiatrist.
Other: data collection and follow-up
Main measures and data collection methods: 1. Recording of baseline demographic and clinical information of the participants. 2. Multimodal magnetic resonance imaging. 3. Heart rate variability. 4. Electroencephalography. 5. Emotion-related questionnaires. 6. Cognitive tests. 7. Behavioral data collection using wearable devices. 8. Blood samples collection.
The 17-item Hamilton Depression Rating Scale (HAMD-17)
The HAMD-17 scale has 17 items. The total score ranges from 0-52, with higher score indicating more severe depressive symptoms. A total score of 0-7 is considered to be normal. Scores of 17 or higher indicate moderate, severe, or very severe depression.
Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year
Change in brain functional connectivity measured by resting-state functional MRI
Resting-state functional magnetic resonance imaging (rs-fMRI) will be employed to evaluate functional connectivity alterations in core brain networks
Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year
Change in Heart Rate Variability (HRV) via wearable device
Change in HRV derived from interbeat intervals (IBIs) collected via wearable device.
Time frame: Within 4 weeks, but not exceeding 1 year.
Change in daily step count and activity patterns recorded via wearable device
Change in daily step count and overall activity patterns automatically recorded via wearable device.
Time frame: Within 4 weeks, but not exceeding 1 year.
Change in Cytokines (reported in pg/mL)
Peripheral blood biomarkers will be measured to evaluate inflammatory and immune responses to treatment. Interferon-α (IFN-α) Interferon-γ (IFN-γ) Interleukin-1β (IL-1β) Interleukin-2 (IL-2) Interleukin-4 (IL-4) Interleukin-5 (IL-5) Interleukin-6 (IL-6) Interleukin-8 (IL-8) Interleukin-10 (IL-10) Interleukin-17 (IL-17) Tumor necrosis factor-alpha (TNF-α)
Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year
Change in Composite Immune-Inflammatory Ratio Index (unitless)
This composite index includes platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and monocyte-to-HDL cholesterol ratio (MHR), which together reflect systemic inflammatory activity and immune status.
Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year
Change in electroencephalographic (EEG) activity measured by resting-state EEG
EEG recordings will be obtained before and after the treatment to evaluate changes in neural oscillatory activity and functional connectivity, including metrics such as power spectral density (alpha, beta bands), coherence, and event-related potentials.
Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year
Change from baseline in the Clinical Global Impression-Severity scale (CGI-S)
The CGI-S is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. A rating of 1 is considered normal, or with the least severe symptoms, a rating of 7 is extremely ill, or the worst symptoms.
Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year
Change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS)
MADRS is a clinician-rated scale used to assess depressive symptom severity and detect changes due to antidepressant treatment. The scale consists of 10 items, each of which is rated from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms). The total score of MADRS ranges from 0 to 60, with higher score indicating more severe depression.
Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year
The Young Mania Rating Scale (YMRS)
he Young Mania Rating Scale (YMRS) is an 11-item clinician-rated scale used to assess the severity of manic symptoms. Each item is scored from 0 to 4 or 0 to 8, depending on symptom intensity, with a total score ranging from 0 to 60. Higher scores indicate more severe manic symptoms. A score below 12 is generally considered to reflect remission or minimal symptoms.
Time frame: at baseline, week 1, week 2, week 4, week 24, and up to 1 year.
Change in Blood Oxygen Saturation
Change in continuously monitored SpO₂ values from wearable sensors.
Time frame: Within 4 weeks, but not exceeding 1 year.
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Mar 2029, 48 months after the start.
Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's planned 48 months is close to that.
Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jiangsu Province Nanjing Brain Hospital